Showing 61-80 of 258 for: EBMG evidence summaries > Pharmacotherapeutics 
- Beta-blockers against other antihypertensive drugs
EBMG evidence summaries, 31-Oct-2005
Beta-blocker (mostly atenolol) treatment for primary hypertension is associated with a higher risk of stroke than treatment with other antihypertensive agents. Compared with placebo, beta-blockers reduce the risk of stroke by 19%, which is about half that
- Beta-carotene and the risk of lung cancer
EBMG evidence summaries, 8-Apr-2007
Beta-carotene appears to increase the risk of lung cancer in smokers.
- Betamimetics for preterm labour
EBMG evidence summaries, 13-Apr-2011
Betamimetics help to delay delivery for women transferred to tertiary care or completing a course of antenatal corticosteroids, but multiple adverse effects must be considered. Maintenance therapy with betamimetics after threatened preterm labour is of no
- Bisphosphonates for steroid induced osteoporosis
EBMG evidence summaries, 20-Mar-2003
Bisphosphonates are effective at preventing and treating corticosteroid-induced bone loss at the lumbar spine and femoral neck.
- Bisphosphonates for the relief of pain secondary to bone metastases
EBMG evidence summaries, 28-Jul-2007
Bisphosphonates appear to give some relief of pain secondary to bone metastases and should be considered when analgesics and/or radiotherapy give inadequate pain relief.
- Bisphosphonates in breast cancer
EBMG evidence summaries, 14-Apr-2012
Bisphosphonates reduce the risk of skeletal events in women with advanced breast cancer and clinically evident bone metastases.
- Bisphosphonates in multiple myeloma
EBMG evidence summaries, 4-Oct-2012
Bisphosphonates appear to prevent pathological vertebral fractures and may reduce pain in multiple myeloma.
- Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis
EBMG evidence summaries, 23-Aug-2007
Bisphosphonates appear to increase the bone mineral density (BMD) in the lumbar spine in patients with glucocorticoid-induced osteoporosis. There is little evidence for this effect in the femoral trochanter, and even less for the femoral neck.
- Bone loss due to corticosteroids
EBMG evidence summaries, 4-Aug-2003
High-dose corticosteroids appear to induce bone loss. Short-term (< 1 year) low dose corticosteroid treatment (< 10 mg prednisone/day) in rheumatoid arthritis patients (RA) may lead to bone loss that is limited in the femoral neck and negligible in the lu
- Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy
EBMG evidence summaries, 15-Apr-2010
Botulinum toxin-A (BoNT-A ) is effective as an adjunct to occupational therapy compared to occupational therapy alone in managing the upper limb in children with spastic cerebral palsy, but BoNT-A alone appears not to be effective.
- Botulinum toxin for cervical dystonia
EBMG evidence summaries, 3-Jan-2006
Botulinum toxin is effective and safe for treating people with cervical dystonia.
- Botulinum toxin for chronic anal fissure
EBMG evidence summaries, 26-Mar-2005
Botulinum toxin may be as effective as glyceryl trinitrate for chronic anal fissure.
- Botulinum toxin injections for spasmodic dysphonia
EBMG evidence summaries, 16-Mar-2010
Botulinum toxin may be effective for some aspects of voice production in patients withs spasmodic dysphonia.
- Botulinum toxin type A for blepharospasm
EBMG evidence summaries, 3-Jan-2006
There are no high quality, randomised, controlled efficacy data to support the use of Botulinum toxin type A (BtA) for blepharospasm, but other studies suggest that BtA may be highly effective and safe for treating blepharospasm.
- Botulinum toxin type A therapy for hemifacial spasm
EBMG evidence summaries, 4-Jan-2006
Botulinum toxin type A (BtA) muscular injections appear to be beneficial in treating hemifacial spasm.
- Botulinum toxin type A versus anticholinergics for cervical dystonia
EBMG evidence summaries, 4-Jan-2006
Botulinum toxin type A injections may provide more objective and subjective benefit than trihexyphenidyl to patients with cervical dystonia.
- Bronchodilators for bronchiolitis
EBMG evidence summaries, 19-Aug-2008
There appears to be a small short-term improvement in clinical features, but no evidence of reduced hospitalisation rate with the use of bronchodilator therapy in acute bronchiolitis.
- Calcium supplementation during pregnancy for preventing hypertensive disorders
EBMG evidence summaries, 18-Aug-2010
Calcium supplementation during pregnancy appears to reduce the risk of pre-eclampsia, hypertension, and the composite outcome maternal death or severe morbidity especially among women at high risk and those with a low calcium intake.
- Calcium supplementation for improving bone mineral density in children
EBMG evidence summaries, 8-Nov-2006
Calcium supplementation in children does not provide such an increase in bone mineral density that would result in a clinically significant decrease in fracture risk.
- Carbamazepine versus phenobarbitone monotherapy for epilepsy
EBMG evidence summaries, 15-Aug-2007
Carbamazepine and phenobarbitone appear to have similar overall efficacy for epilepsy, however phenobarbitone appears to be more effective for partial onset seizures and carbamazepine for generalized onset tonic-clonic seizures.
